Search
forResearch 10 of 1000+
- Innovations in skin microphysiological systems for nonclinical testing and FDA modernization
- Sustainable UV approaches supported by greenness and whiteness assessments for estimating a recently FDA-approved combination for managing urologic disorders: Tukey's test
- The Growing Role for Platelet Rich Plasma in Cosmetic Dermatology
- Androgenetic alopecia (male pattern hair loss) in the United States: What treatments should primary care providers recommend?
- Testosterone Therapy in Women: A Literature Review of Clinical Indications, Dosing, Routes of Administration, and Safety
- PSS21 GAP ANALYSIS FOR PATIENT-REPORTED OUTCOMES MEASURES FOR ALOPECIA
- New changes in pregnancy and lactation labelling: Review of dermatologic drugs
- The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta‐Analysis Study
- View Point- Synthetic hairs: Should they be used?
- Shedding light on the FDA’s 510(k) approvals process: low-level laser therapy devices used in the treatment of androgenetic alopecia
Community 10 of 75
- Just FYI, Here are pictures of 6 months results on Clascoterone 5%. Is it remarkable? No. But it seems likely to be FDA approved considering 1% is already available. This is a win, especially if you pair it with other treatments like Finasteride.
- New warning by FDA on topical finasteride
- Dutasteride would have been approved for AGA by the US FDA.
- Finasteride alternative close to fda approval in the US
- Peeps who arent able to get gains even after using fda approved meds
- Following the recent IPO and the positive Phase 3 clinical data for VDPHL01 (extended-release oral minoxidil), what is the projected timeline for the FDA submission and the subsequent commercial availability on the market?
- FDA Policy Shift Explained: What It Actually Means for PP405, VDPHL-01, Breezula and Hair Loss Drug Timelines
- There’s actually a quite good chance that next year, we might see a new treatment get FDA approval for the first time in nearly three decades.
- Good news for stem cells hair therapies - US federal judge: using patients' stem cells does NOT fall under FDA jurisdiction
- US FDA will now default to only one clinical trial for drug applications, will this accelerate the release of PP405 and other drugs in clinical trials?
Learn
— no results
Try a deeper search in learn →